In another experiment, an injection of the medication inside the peritoneum led to the regression of KRAS-mutated pancreatic adenocarcinoma xenografts compared to control animals, in a dose-dependent fashion [55]. The gene discussed is KRAS; the disease is pancreatic adenocarcinoma.